Literature DB >> 9471021

Disease progression in gastro-oesophageal reflux disease as determined by repeat oesophageal pH monitoring and endoscopy 3 to 4.5 years after diagnosis.

N I McDougall1, B T Johnston, J S Collins, R J McFarland, A H Love.   

Abstract

OBJECTIVES: Reflux oesophagitis may progress to complications such as Barrett's mucosa and stricture formation. However, few studies have assessed long-term disease progression in oesophagitis patients and fewer still have considered disease progression in the significant proportion of gastro-oesophageal reflux disease (GORD) patients who do not have oesophagitis at diagnosis. The aim of this study was to reassess GORD patients 3 to 4 years after initial diagnosis and determine whether or not disease progression had occurred.
METHODS: Prospective follow-up of 101 GORD patients at least 32 months after initial assessment with oesophageal pH monitoring and upper gastrointestinal endoscopy. Patients were invited to complete a symptomatic questionnaire and undergo repeat investigation with the same techniques.
RESULTS: Seventy-seven (76%) patients responded (mean follow-up period 39 months, range 32-54 months) of whom 28 initially had oesophagitis (group A), 17 had normal endoscopy but abnormal pH monitoring (group B) and 32 had normal investigations but typical reflux symptoms (group C). At the time of follow-up, 57 (74%) patients either had frequent heartburn or were taking daily acid suppression therapy. Fifty-two (68%) responders had at least one repeat investigation: 44 (57%) had repeat pH monitoring; 43 (56%) had repeat endoscopy. Three (11% of the 28 responders) group A patients had developed Barrett's mucosa, 4 (24% of responders) group B patients had developed oesophagitis and 10 (31% of responders) group C patients had developed abnormal pH monitoring (4), oesophagitis (4) or both (2).
CONCLUSION: Three-quarters of GORD patients still have troublesome symptoms at least 3 years after diagnosis and a significant proportion show endoscopic progression of the condition's severity.

Entities:  

Mesh:

Year:  1997        PMID: 9471021

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  7 in total

1.  Functional Gastroesophageal Reflux Disease (GERD).

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-08

2.  Endoscopic surveillance in Barrett's oesophagus.

Authors:  J Ryan
Journal:  Gut       Date:  2003-04       Impact factor: 23.059

3.  Functional heartburn, nonerosive reflux disease, and reflux esophagitis are all distinct conditions--a debate: pro.

Authors:  Tomás Navarro-Rodriguez; Ronnie Fass
Journal:  Curr Treat Options Gastroenterol       Date:  2007-08

4.  Nonerosive Reflux Disease (NERD) - An Update.

Authors:  Tiberiu Hershcovici; Ronnie Fass
Journal:  J Neurogastroenterol Motil       Date:  2010-01-31       Impact factor: 4.924

Review 5.  Endoscopic therapy for GERD: does it have a future?

Authors:  Marvin Ryou; Christopher C Thompson
Journal:  Curr Gastroenterol Rep       Date:  2008-06

6.  Severe erosive esophagitis developing after gastric ulcer formation.

Authors:  Takatsugu Yamamoto; Koichiro Abe; Hajime Anjiki; Taro Ishii; Yasushi Kuyama
Journal:  J Clin Med Res       Date:  2012-09-12

7.  Association of sleep dysfunction and emotional status with gastroesophageal reflux disease in Korea.

Authors:  Ji Yeon Kim; Nayoung Kim; Pyoung Ju Seo; Jung Won Lee; Min Soo Kim; Sung Eun Kim; So Young Jo; Dong Ho Lee; Hyun Chae Jung
Journal:  J Neurogastroenterol Motil       Date:  2013-07-08       Impact factor: 4.924

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.